

CRYSTALLINE FORMS OF 'R-(R\*,R\*)-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-' (PHENYLAMINO) CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID

## FIELD OF THE INVENTION

5           The present invention relates to novel crystalline forms of atorvastatin free acid which is known by the chemical name [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta$ ,  $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, useful as intermediates to prepare pharmaceutically acceptable salts of atorvastatin, including atorvastatin calcium, and useful as pharmaceutical agents, to methods for their production and isolation to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, as well as methods of using such compositions to treat subjects, including human subjects, suffering from hyperlipidemia, hypercholesterolemia, benign prostatic hyperplasia, osteoporosis, and Alzheimer's Disease.

10


## 15           BACKGROUND OF THE INVENTION

          The conversion of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate is an early and rate-limiting step in the cholesterol biosynthetic pathway. This step is catalyzed by the enzyme HMG-CoA reductase. Statins inhibit HMG-CoA reductase from catalyzing this conversion. As such, statins are collectively potent lipid lowering agents.

20

          Atorvastatin calcium is currently sold as Lipitor<sup>®</sup> having the chemical name [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) trihydrate and the formula:

-2-



The nonproprietary name designated by USAN (United States Adopted Names) is atorvastatin calcium and by INN (International Nonproprietary Name) is atorvastatin. Under the established guiding principles of USAN, the salt is included in the name whereas under INN guidelines, a salt description is not included in the name.

Atorvastatin and pharmaceutically acceptable salts thereof are selective, competitive inhibitors of HMG-CoA reductase. As such, atorvastatin calcium is a potent lipid lowering compound and is thus useful as a hypolipidemic and/or hypocholesterolemic agent, as well as in the treatment of osteoporosis, benign prostatic hyperplasia, and Alzheimer's disease.

A number of patents have issued disclosing atorvastatin calcium, formulations of atorvastatin calcium, as well as processes and key intermediates for preparing atorvastatin calcium. These include: United States Patent Numbers 4,681,893; 5,273,995; 5,003,080; 5,097,045; 5,103,024; 5,124,482; 5,149,837; 5,155,251; 5,216,174; 5,245,047; 5,248,793; 5,280,126; 5,397,792; 5,342,952; 5,298,627; 5,446,054; 5,470,981; 5,489,690; 5,489,691; 5,510,488; 5,686,104; 5,998,633; 6,087,511; 6,126,971; 6,433,213; and 6,476,235, which are herein incorporated by reference.

Atorvastatin calcium can exist in crystalline, liquid-crystalline, non-crystalline and amorphous forms.

Crystalline forms of atorvastatin calcium are disclosed in United States Patent Numbers 5,969,156 and 6,121,461 which are herein incorporated by reference. Further crystalline, liquid crystalline, plastic crystalline, disordered

-3-

forms and non-crystalline forms, as well as mesophases are disclosed in copending applications: Published International Patent Application WO 03/004470 and United States Patent Application serial number 60/414,734, which are herein incorporated by reference.

5           Additionally, a number of published International Patent Applications have disclosed crystalline forms of atorvastatin calcium, as well as processes for preparing amorphous atorvastatin calcium. These include: WO 00/71116; WO 01/28999; WO 01/36384; WO 01/42209; WO 02/41834; WO 02/43667; WO 02/43732; WO 02/051804; WO 02/057228; WO 02/057229; WO 02/057274; WO 10 02/059087; WO 02/072073; WO 02/083637; WO 02/083638; and WO 02/089788.

Atorvastatin is prepared as its calcium salt, i.e., [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-1-heptanoic acid calcium salt (2:1). The calcium salt is desirable since it enables atorvastatin to be conveniently 15 formulated in, for example, tablets, capsules, lozenges, powders, and the like for oral administration.

Atorvastatin free acid, disclosed in US Patent 5,213,995, can be used to prepare the calcium salt of atorvastatin, as well as other pharmaceutically acceptable basic addition salts of atorvastatin. Additionally, atorvastatin free acid 20 can be used as a pharmaceutical agent. However, prior to the present invention, atorvastatin free acid could only be isolated as an oil. Therefore, there was a need to prepare atorvastatin free acid in solid, preferably crystalline, form to facilitate the preparation of salts of atorvastatin, as well as pharmaceutical compositions containing the free acid of atorvastatin.

25           We have now surprisingly and unexpectedly found novel crystalline forms of atorvastatin free acid. Thus, the present invention provides atorvastatin free acid in new crystalline forms designated Forms A and B. The new crystalline forms of atorvastatin free acid are purer, more stable, and have advantageous properties compared to the prior non-crystalline form.

30

-4-

## SUMMARY OF THE INVENTION

Accordingly, a first aspect of the present invention is directed to crystalline forms of atorvastatin free acid and hydrates thereof.

5 In a second aspect, the invention is directed to crystalline Form A atorvastatin free acid and hydrates thereof characterized by the following x-ray powder diffraction pattern expressed in terms of the  $2\theta$ , d-spacings, and relative intensities with a relative intensity of >20% measured on a Bruker D5000 diffractometer with  $\text{CuK}\alpha$  radiation:

Degree $2\theta$	d (Å)	Relative Intensity (>20%)
4.7	18.7	49.5
6.0	14.6	25.9
8.9	9.9	46.0
9.1	9.8	63.0
9.4	9.4	100.0
13.2	6.7	20.5
14.1	6.3	29.5
17.8	5.0	55.8
18.1	4.9	98.1
18.9	4.7	63.8
19.9	4.5	23.9
20.2	4.4	29.3
20.6	4.3	32.4
21.8	4.1	50.1
22.1	4.0	57.5
22.5	4.0	28.4
23.7	3.8	57.1
25.9	3.4	21.0
26.7	3.3	20.0

10 \*The relative intensities may change depending on the crystal size and morphology.

Further, in a third aspect, the present invention is directed to crystalline Form A atorvastatin free acid and hydrates thereof characterized by the following solid-state  $^{13}\text{C}$  nuclear magnetic resonance (SSNMR) spectrum wherein chemical  
15 shift is expressed in parts per million (ppm):

Assignment	Carbon chemical shift (ppm)*
C39	180.6
C39	174.3

-5-

	C 8	167.1
	C 8	166.3
	C27	163.6
	C27	161.5
5	Following group of resonances include: C1, 2, 3,4, 6, 7, 9, 10, 12, 13, 17, 18, 20, 21, 24, 25, 28, 29, 33, 34,36	141.8
		140.7
		137.9
10		135.2
		134.1
		132.9
		130.0
		128.8 (shoulder)
15		128.0
		125.4
		123.3
		121.6
		119.3
20		118.4
		116.4
		115.1
		113.7
		112.3
25	Following group of resonances include: C26, 35	71.3
		70.0
		69.1
30		68.6
		65.3
35	Following group of resonances include: C11, 19,30,37	43.5
		42.9
		41.8
		40.6
		40.0
40		38.9
		37.1
45	Following group of resonances include: C14,22,23	26.8
		26.2
		25.5
		25.0
		21.2
		20.5

-6-

18.8  
18.1Peak at 8.4 ppm is a spinning side band

- 5 \*Values in ppm with respect to tetramethylsilane (TMS) at 0 ppm; referenced using an external sample of adamantane, setting is upfield resonance to 29.5 ppm.

10 Additionally, in a fourth aspect, the present invention is directed to crystalline Form A atorvastatin free acid and hydrates thereof characterized by the following solid-state  $^{19}\text{F}$  nuclear magnetic resonance spectrum wherein chemical shift is expressed in parts per million:

Assignment	Flourine chemical shift (ppm)*
F	-105.6
	-110.6
	-112.6
	-114.1

15

\*Values in ppm with respect to  $\text{CCl}_3\text{F}$  at 0 ppm; referenced by setting  $^{19}\text{F}$  signal of trifluoroacetic acid (TFA) - $\text{H}_2\text{O}$  (1:1) to -76.54 ppm.

- 20 In a fifth aspect, the present invention is directed to crystalline Form B atorvastatin free acid and hydrates thereof characterized by the following x-ray powder diffraction pattern expressed in terms of the  $2\theta$ , d-spacings, and relative intensities with a relative intensity of >20% measured on a Bruker D5000 diffractometer with  $\text{CuK}\alpha$  radiation:

Degree $2\theta$	d ( $\text{\AA}$ )	Relative* Intensity (>20%)
4.6	19.0	48.3
5.9	15.0	32.4
8.6	10.2	46.6
9.3	9.5	100.0
13.3	6.6	33.7
14.1	6.3	33.4
17.4	5.1	46.7
17.7	5.0	43.1
18.0	4.9	77.0
18.8	4.7	66.4
19.3	4.6	21.5
19.8	4.5	23.5
20.2	4.4	21.5
21.1	4.2	36.7
21.5	4.1	38.3
21.9	4.1	31.6
23.6	3.8	44.8

-7-

\*The relative intensities may change depending on the crystal size and morphology.

As inhibitors of HMG-CoA reductase, the novel crystalline forms of atorvastatin free acid are useful as hypolipidemic and hypocholesterolemic agents, as well as agents in the treatment of osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

A still further embodiment of the present invention is a pharmaceutical composition for administering an effective amount of crystalline Form A or Form B atorvastatin free acid in unit dosage form in the treatment methods mentioned above. Finally, the present invention is directed to methods for production of Forms A and B atorvastatin free acid.

### BRIEF DESCRIPTION OF THE DRAWINGS

The invention is further described by the following nonlimiting examples which refer to the accompanying Figures 1 to 4, short particulars of which are given below.

15     Figure 1

Diffractiongram of Form A atorvastatin free acid carried out on a Bruker D5000 diffractometer.

Figure 2

20     Diffractiongram of Form B atorvastatin free acid carried out on a Bruker D5000 diffractometer.

Figure 3

Solid-state  $^{13}\text{C}$  nuclear magnetic resonance spectrum of Form A atorvastatin free acid.

Figure 4

25     Solid-state  $^{19}\text{F}$  nuclear magnetic resonance spectrum of Form A atorvastatin free acid.

## DETAILED DESCRIPTION OF THE INVENTION

The term "crystalline" as used herein refers to a solid formed by a repeating three-dimensional pattern of atoms, ions or molecules and having fixed distances between the constituent parts and furthermore, can be identified by one skilled in the art using methods, such as, for example x-ray diffraction, solid-state NMR, Raman spectroscopy, Infrared spectroscopy and the like. Examples of crystalline solids disclosed in the present application include crystalline Form A and Form B atorvastatin free acid. Crystalline Form A and Form B atorvastatin free acid may be characterized by their x-ray powder diffraction patterns and/or by their solid state nuclear magnetic resonance spectra.

**Powder X-ray Diffraction**

Forms A and B atorvastatin free acid were characterized by their powder x-ray diffraction patterns. Thus, the x-ray diffraction patterns of Forms A and B were carried out on a Bruker D5000 diffractometer using copper radiation (wavelength 1:1.54056. The tube voltage and amperage were set to 40 kV and 50mA, respectively. The divergence and scattering slits were set at 1 mm, and the receiving slit was set at 0.6 mm. Diffracted radiation was detected by a Kevex PSI detector. A theta-two theta continuous scan at 2.4 °/min (1 sec/0.04° step) from 3.0 to 40 ° 2 $\theta$  was used. An alumina standard was analyzed to check the instrument alignment. Data were collected and analyzed using Bruker axis software Version 7.0. Samples were prepared by placing them in a quartz holder. It should be noted that Bruker Instruments purchased Siemens; thus, Bruker D5000 instrument is essentially the same as a Siemens D5000.

Table 1 lists the 2 $\theta$  and relative intensities of all lines that have a relative intensity of >20% in the sample for crystalline Forms A and B atorvastatin free acid:

TABLE 1: INTENSITIES AND PEAK LOCATIONS OF DIFFRACTION LINES FOR ATORVASTATIN FREE ACID, FORMS A AND B

FORM A		FORM B	
Degree 2 $\theta$	Relative Intensity	Degree 2 $\theta$	Relative Intensity



-9-

	(>20%)		(>20%)
4.7	49.5	4.6	48.3
6.0	25.9	5.9	32.4
8.9	46.0	8.6	46.6
9.1	63.0	9.3	100.0
9.4	100.0	13.3	33.7
13.2	20.5	14.1	33.4
14.1	29.5	17.4	46.7
17.8	55.8	17.7	43.1
18.1	98.1	18.0	77.0
18.9	63.8	18.8	66.4
19.9	23.9	19.3	21.5
20.2	29.3	19.8	23.5
20.6	32.4	20.2	21.5
21.8	50.1	21.1	36.7
22.1	57.5	21.5	38.3
22.5	28.4	21.9	31.6
23.7	57.1	23.6	44.8
25.9	21.0		
26.7	20.0		

Because only two crystalline forms of atorvastatin free acid are known, each form can be identified and distinguished from the other crystalline form by either a single x-ray powder diffraction line, a combination of lines or a pattern that is different from the x-ray powder diffraction of the other form.

For example, Table 2 lists single unique 2 $\theta$  peaks for Forms A and B atorvastatin free acid, i.e., a set of x-ray diffraction lines that are unique to each form.

TABLE 2: ATORVASTATIN FREE ACID, FORMS A AND B UNIQUE PEAKS AND COMBINATIONS OF 2 $\theta$  PEAKS

FORM A Degree 2 $\theta$	FORM B Degree 2 $\theta$
8.9	8.6
20.6	17.4
22.5	21.1
25.9	21.5

-10-

### Solid State Nuclear Magnetic Resonance

Form A atorvastatin free acid may also be characterized by its solid-state nuclear magnetic resonance spectra. Thus, the solid-state nuclear magnetic resonance spectra of Form A was carried out on a Bruker-Biospin Avance DSX 500 MHz NMR spectrometer.

#### <sup>19</sup>F SSNMR

Approximately 15 mg of sample were tightly packed into a 2.5 mm ZrO spinner for each sample analyzed. One-dimensional <sup>19</sup>F spectra were collected at 295 K and ambient pressure on a Bruker-Biospin 2.5 mm BL cross-polarization magnetic angle spinning (CPMAS) probe positioned into a wide-bore Bruker-Biospin Avance DSX 500 MHz NMR spectrometer. The samples were positioned at the magic angle and spun at 35.0 kHz, corresponding to the maximum specified spinning speed for the 2.5 mm spinners. The fast spinning speed minimized the intensities of the spinning side bands and provided almost complete decoupling of <sup>19</sup>F signals from protons. The number of scans were individually adjusted for each sample to obtain adequate single/noise (S/N). Typically, 150 scans were acquired. Prior to <sup>19</sup>F acquisition, <sup>19</sup>F relaxation times were measured by an inversion recovery technique. The recycle delay for each sample was then adjusted to five times the longest <sup>19</sup>F relaxation time in the sample, which ensured acquisition of quantitative spectra. A background due to probe ringing was subtracted in each alternate scan after presaturating the <sup>19</sup>F signal. The spectra were referenced using an external sample of trifluoroacetic acid (diluted to 50% V/V by H<sub>2</sub>O), setting its resonance to -76.54 ppm.

#### <sup>13</sup>C SSNMR

Approximately 80 mg of sample were tightly packed into a 4 mm ZrO spinner for each sample analyzed. One-dimensional <sup>13</sup>C spectra were collected at ambient pressure using <sup>1</sup>H-<sup>13</sup>C CPMAS at 295 K on a Bruker 4 mm BL CPMAS probe positioned into a wide-bore Bruker-Biospin Avance DSX 500 MHz NMR spectrometer. The samples were spun at 15.0 kHz corresponding to the maximum specified spinning speed for the 4mm spinners. The fast spinning speed minimized the intensities of the spinning side bands. To optimize the signal sensitivity, the cross-polarization contact time was adjusted to 1.5 ms, and the proton decoupling power was set to 100 kHz. The number of scans were

-11-

individually adjusted for each sample to obtain adequate S/N. Typically, 1900 scans were acquired with a recycle delay of 5 seconds. The spectra were referenced using an external sample of adamantane, setting its upfield resonance at 29.5 ppm.

5           Atorvastatin free acid crystalline Forms A and B of the present invention may exist in anhydrous forms as well as hydrated and solvated forms. In general, the hydrated forms are equivalent to unhydrated forms and are intended to be encompassed within the scope of the present invention. Crystalline Form A preferably occurs as a hydrate. Preferably, Form A contains 0.6 mol of water.

10           Atorvastatin free acid crystalline Forms A and B of the present invention, regardless of the extent of hydration and/or solvation having equivalent x-ray powder diffractograms, or SSNMR, are within the scope of the present invention.

          The new crystalline forms of atorvastatin free acid described herein have advantageous properties. For example, Forms A and B have good chemical  
15           stability. Also, the solubility of Forms A and B in solvents including water and phosphate buffered saline solution are comparable to Form I atorvastatin calcium (disclosed in United States Patent Number 5,969,156).

          The present invention provides a process for the preparation of crystalline Forms A and B atorvastatin free acid which comprises crystallizing atorvastatin  
20           free acid from a solution in solvents under conditions which yield crystalline Forms A and B atorvastatin free acid.

          The precise conditions under which crystalline Forms A and B atorvastatin free acid are formed may be empirically determined, and it is only possible to give a number of methods which have been found to be suitable in practice.

25           For example, Form A can be prepared by slurring atorvastatin calcium in water with a solvent such as, for example, acetonitrile and the like. The mixture is filtered and the filtrate is acidified with an acid such as, for example, an inorganic acid such as hydrochloric acid and the like, followed by removal of the solvent. The solid is washed with water and dried to afford Form A. Preferably, crystalline  
30           Form I atorvastatin calcium is slurried in a mixture of about 80 parts of water and 20 parts of acetonitrile, the mixture is filtered, the filtrate is acidified with 1N HCl, the solvent removed, the resulting solid washed with water and dried at about room temperature for about 24 hours to afford Form A.

-12-

Alternatively, Form A may be prepared by solvent extraction. For example, atorvastatin calcium is slurried in water until wet, followed by the addition of a solvent such as, for example, methyl tertiary butyl ether (MTBE), ethyl acetate and the like. The suspension is acidified with an acid as disclosed above, stirred until a clear two phase mixture results, the organic phase is separated, the solvent removed, and the resulting solid is dissolved in a solvent such as water and acetonitrile to afford Form A. Seeds of Form A can be added after the solid is dissolved in water-acetonitrile to accelerate the formation of Form A. Preferably, crystalline Form I atorvastatin calcium is slurried in a mixture of water and MTBE, the suspension is acidified with 1N HCl, the two phases are separated, the MTBE is removed, the resulting solid is dissolved in water-acetonitrile, seeds of Form A are added and Form A is isolated by filtration.

Form B is prepared by heating Form A at about 45°C under vacuum for about one day. Preferably, Form A is heated in a oven at about 45°C under vacuum for about one day. Alternatively, Form A is exposed to low relative humidity for about 72 days to afford Form B. Preferably, Form A is stored in a low relative humidity chamber prepared using phosphorous pentoxide for about 72 days to afford Form B.

The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

-13-

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from two or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, retention enemas, and emulsions, for example water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.

-14-

Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

5           The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit  
10       dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

          The quantity of active component in a unit dose preparation may be varied or adjusted from 0.5 mg to 100 mg, preferably 2.5 mg to 80 mg according to the particular application and the potency of the active component. The composition  
15       can, if desired, also contain other compatible therapeutic agents.

          In therapeutic use as hypolipidemic and/or hypocholesterolemic agents and agents to treat osteoporosis, benign prostatic hyperplasia, and Alzheimer's disease, crystalline Forms A and B atorvastatin free acid utilized in the pharmaceutical method of this invention are administered at the initial dosage of  
20       about 2.5 mg to about 80 mg daily. A daily dose range of about 2.5 mg to about 20 mg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller  
25       dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

          The following nonlimiting examples illustrate the inventors' preferred  
30       methods for preparing the compounds of the invention.

-15-

## EXAMPLE 1

[R-(R\*,R\*)]-2-(4-Fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid.

5      **Form A Atorvastatin Free Acid**Method A

In a 600 mL beaker, a slurry was prepared by charging 100 mL of acetonitrile (ACN) and 400 mL deionized water (20:80 ACN:water) to 0.5 grams of crystalline Form I atorvastatin calcium (US Patent 5,969,156). The slurry was stirred at ambient conditions for 15 minutes. All undissolved material was removed by vacuum filtration using a 0.45 $\mu$ m nylon-66 membrane filter. The pH of the filtrate was determined to be 6.5 - 7.0, which was then adjusted to pH 2.35 with 1N HCl. A cloudy precipitate formed and determined by PLM to be fine droplets of oil. Solvent was evaporated by passing nitrogen over the headspace of the solution with stirring until a heavy white precipitate formed (~15 minutes). The slurry was vacuum filtered through a 0.45 $\mu$ m nylon-66 membrane filter. The solids were then washed with 100 mL of deionized water and air dried at ambient conditions for 24 hours to afford 0.3 grams of crystalline Form A atorvastatin free acid.

20      Method B

Crystalline Form I atorvastatin calcium (US Patent 5,969,156) (10 grams) was placed in an Erlenmeyer flask (4 L). Water (1L) was added to the flask along with a magnetic stir bar. The contents were stirred until all of the solids were wet. With stirring, MTBE (methyl *tert*-butyl ether - 1 L) was added to the reaction mixture to form a white suspension. Hydrochloric Acid (20 mL - 1 N solution) was then added to the suspension with stirring. The contents were stirred until a clear mixture (2 phases) was present (ca. 5 min). The mixture was then transferred into a separatory funnel (4L). The contents were mixed well, and the layers separated. The water layer (lower phase) was placed back into the separatory funnel and additional MTBE (1 L) was added. The contents were mixed well, and the layers were separated. The water layer was discarded, and the MTBE layer was combined with the MTBE layer from the first extraction. The combined

-16-

MTBE layers were placed back into the funnel and water was added (0.5 L). The contents were mixed well, and the layers were separated. The water layer was discarded, and the MTBE layer was placed into a round-bottomed flask (3 L). The MTBE was then removed via rotary evaporation producing a thin film or  
5 amorphous solid. The film/solid was dissolved with acetonitrile (0.2 L) to form a solution. Water (0.8 L) was added to the solution with stirring using a magnetic stir bar. A white suspension was formed that appeared as oil droplets by PLM (polarized-light microscopy). Seed crystals of Form A atorvastatin free acid were added. The contents were then rapidly stirred under a nitrogen bleed for  
10 approximately one hour. The solids were isolated by vacuum filtration using a Büchner funnel fitted with a paper filter (#2). The solids were rinsed using water (0.5 L), and placed in a crystallizing dish. The dish was placed in an oven at 25°C maintaining nitrogen until dry (ca. 1 day). This procedure afforded crystalline Form A atorvastatin free acid in a yield of approximately 92%.

#### 15 **Form B Atorvastatin Free Acid**

##### Method A

Crystalline Form A atorvastatin free acid (Example 1) was stored in a vacuum oven at 45°C (nitrogen purge, house vacuum) for about one day to afford crystalline Form B atorvastatin free acid.

#### 20 Method B

Crystalline Form A atorvastatin free acid (Example 1) was stored in a low relative humidity chamber (prepared using phosphorous pentoxide) for about 72 days to afford crystalline Form B atorvastatin free acid.



-17-

## CLAIMS

What is claimed is:


1. A crystalline atorvastatin free acid.
2. A crystalline Form A atorvastatin free acid or a hydrate thereof having a  
5 X-ray powder diffraction pattern containing the following  $2\theta$  values  
measured using  $\text{CuK}\alpha$  radiation: 8.9, 20.6, 22.5, or 25.9.
3. A crystalline Form A atorvastatin free acid or a hydrate thereof having a  
X-ray powder diffraction pattern containing the following  $2\theta$  values  
measured using  $\text{CuK}\alpha$  radiation: 4.7, 6.0, 8.9, 9.1, 9.4, 13.2, 14.1, 17.8,  
10 18.1, 18.9, 19.9, 20.2, 20.6, 21.8, 22.1, 22.5, 23.7, 25.9, and 26.7.
4. A crystalline Form A atorvastatin free acid hydrate thereof having a X-ray  
powder diffraction pattern containing the following  $2\theta$  values measured  
using  $\text{CuK}\alpha$  radiation: 8.9, 20.6, 22.5, or 25.9.
5. A crystalline Form A atorvastatin free acid hydrate thereof having a X-ray  
15 powder diffraction pattern containing the following  $2\theta$  values measured  
using  $\text{CuK}\alpha$  radiation: 4.7, 6.0, 8.9, 9.1, 9.4, 13.2, 14.1, 17.8, 18.1, 18.9,  
19.9, 20.2, 20.6, 21.8, 22.1, 22.5, 23.7, 25.9, and 26.7.
6. A crystalline Form A atorvastatin free acid or a hydrate thereof  
characterized by solid-state  $^{13}\text{C}$  nuclear magnetic resonance having the  
20 following chemical shifts expressed in parts per million: 18.1, 18.8, 20.5,  
and 21.2.
7. A crystalline Form A atorvastatin free acid or a hydrate thereof  
characterized by solid-state  $^{13}\text{C}$  nuclear magnetic resonance having the  
following chemical shifts expressed in parts per million: 161.5, 163.6,  
25 166.3, 167.1, 174.3, and 180.6.

-18-

8. A crystalline Form A atorvastatin free acid or a hydrate thereof characterized by solid-state  $^{13}\text{C}$  nuclear magnetic resonance having the following chemical shifts expressed in parts per million: 18.1, 18.8, 20.5, 21.2, 25.0, 25.5, 26.2, 26.8, 37.1, 38.9, 40.0, 40.6, 41.8, 42.9, 43.5, 65.3, 68.6, 69.1, 70.0, 71.3, 112.3, 113.7, 115.1, 116.4, 118.4, 119.3, 121.6, 123.3, 125.4, 128.0, 128.8 (shoulder), 130.0, 132.9, 134.1, 135.2, 137.9, 140.7, 141.8, 161.5, 163.6, 166.3, 167.1, 174.3, and 180.6.
9. A crystalline Form A atorvastatin free acid or a hydrate thereof characterized by solid state  $^{19}\text{F}$  nuclear magnetic resonance having the following chemical shift expressed in parts per million: -114.1, -112.6, -110.6, or -105.6.
10. A crystalline Form A atorvastatin free acid hydrate thereof characterized by solid state  $^{19}\text{F}$  nuclear magnetic resonance having the following chemical shift expressed in parts per million: -114.1, -112.6, -110.6, or -105.6.
11. A crystalline Form B atorvastatin free acid or a hydrate thereof having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 8.6, 17.4, 21.1, or 21.5.
12. A crystalline Form B atorvastatin free acid or hydrate thereof having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 4.6, 5.9, 8.6, 9.3, 13.3, 14.1, 17.4, 17.7, 18.0, 18.8, 19.3, 19.8, 20.2, 21.1, 21.5, 21.9, and 23.6.
13. A crystalline Form B atorvastatin free acid having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 4.6, 5.9, 8.6, 9.3, 13.3, 14.1, 17.4, 17.7, 18.0, 18.8, 19.3, 19.8, 20.2, 21.1, 21.5, 21.9, and 23.6.

-19-

14. A pharmaceutical composition comprising crystalline atorvastatin free acid in admixture with at least one pharmaceutically acceptable excipient, diluent, or carrier.
- 5 15. A method of treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.

**FIG. 1**






FIG. 3



**FIG. 4**

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB2004/002919

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07D207/34 A61K31/40 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 583 295 B1 (PFLAUM ZLATKO) 24 June 2003 (2003-06-24) example 22	1-15
A	WO 02/43667 A (ISHAI ETI ; TEVA PHARMA (IL); NIDDAM VALERIE (IL); LIDOR HADAS RAMY (I) 6 June 2002 (2002-06-06) example 1	1-15
A	US 4 681 893 A (ROTH BRUCE D) 21 July 1987 (1987-07-21) column 13, line 50 - line 54 column 1, line 9 - line 20	1-15

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

24 November 2004

Date of mailing of the international search report

08/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Seymour, L



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB2004/002919

## Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 15 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB2004/002919

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6583295	B1	24-06-2003	SI 20070 A 30-04-2000
			AT 271026 T 15-07-2004
			AU 765373 B2 18-09-2003
			AU 5528599 A 10-04-2000
			CA 2343646 A1 30-03-2000
			DE 69918697 D1 19-08-2004
			EP 1114021 A1 11-07-2001
			JP 2002526467 T 20-08-2002
			NZ 509583 A 31-10-2003
			CN 1318046 T 17-10-2001
			EP 1466886 A2 13-10-2004
			HU 0103007 A2 29-05-2002
			WO 0017150 A1 30-03-2000
			US 2003120086 A1 26-06-2003
WO 0243667	A	06-06-2002	AU 3289102 A 11-06-2002
			CA 2427255 A1 06-06-2002
			CZ 20031595 A3 12-11-2003
			EP 1341785 A2 10-09-2003
			HU 0303555 A2 01-03-2004
			JP 2004514687 T 20-05-2004
			NO 20032200 A 24-06-2003
			SK 7212003 A3 02-03-2004
			WO 0243667 A2 06-06-2002
			US 2002099224 A1 25-07-2002
			AU 1792702 A 11-06-2002
			BR 0115892 A 28-10-2003
			CA 2429590 A1 06-06-2002
			CN 1489463 T 14-04-2004
			CZ 20031766 A3 18-08-2004
			DE 01998348 T1 26-08-2004
			EP 1363621 A1 26-11-2003
			ES 2215495 T1 16-10-2004
			JP 2004514694 T 20-05-2004
			NO 20032425 A 25-07-2003
			SK 8062003 A3 07-07-2004
			TR 200400815 T3 21-07-2004
			WO 0243732 A1 06-06-2002
			US 2003212279 A1 13-11-2003
			US 2002183378 A1 05-12-2002
			LT 2004018 A 27-09-2004
US 4681893	A	21-07-1987	AT 60602 T 15-02-1991
			AU 601981 B2 27-09-1990
			AU 7315987 A 03-12-1987
			CA 1268768 A1 08-05-1990
			DE 3767770 D1 07-03-1991
			DK 171588 B1 10-02-1997
			EP 0247633 A1 02-12-1987
			FI 872365 A ,B, 01-12-1987
			GR 3001415 T3 25-09-1992
			HK 119493 A 12-11-1993
			IE 60014 B1 18-05-1994
			JP 2019432 C 19-02-1996
			JP 7057751 B 21-06-1995
			JP 62289577 A 16-12-1987
			KR 9401006 B1 08-02-1994
			LU 90147 A9 10-12-1997

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB2004/002919

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4681893	A	MX 9203095 A1	01-07-1992
		NL 970034 I1	03-11-1997
		NO 872259 A ,B,	01-12-1987
		NZ 220409 A	27-10-1989
		PH 24661 A	07-09-1990
		PH 26330 A	29-04-1992
		PT 84975 A ,B	01-06-1987
		ZA 8703438 A	28-12-1988